Magdalena Bofill Rodriguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magdalena Bofill Rodriguez has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Anne Lethaby
Department of Obstetrics, Gynaecology and Reproductive Sciences; University of Auckland; Auckland New Zealand
7 shared publicationsCindy Farquhar
Department of Obstetrics, Gynaecology and Reproductive Sciences; University of Auckland; Auckland New Zealand
5 shared publicationsJack Wilkinson
Centre for Biostatistics, School of Health Sciences, Faculty of Biology, Medicine and Health Manchester Academic Health Science Centre (MAHSC), University of Manchester Manchester UK
2 shared publicationsJames Mn Duffy
King's Fertility; Fetal Medicine Research Institute; London UK
2 shared publicationsVanessa Jordan
Department of Obstetrics and Gynaecology, Faculty of Medical and Health Sciences The University of Auckland Auckland New Zealand
2 shared publicationsChristine Bekos
Vienna Austria
1 shared publication
Latest Publications
- 27 November 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (11) , CD004143
Long-term hormone therapy for perimenopausal and postmenopausal women
Background Hormone therapy is widely provided to control menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. Objectives To assess the long‐term effects of prolonged use (at least one year) of hormone therapy on mortality, cardiovascular outcomes, cancer, gallbladder disease, fractures and cognition in perimenopausal and postmenopausal women. Search methods We used the Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL, MEDLINE, three other databases and two trial registers, together with reference checking, citation searching and contact with study authors to identify the studies included in the review. The latest search date was 26 September 2024. Selection criteria We included randomised, double‐blind trials in which peri‐ or postmenopausal women took hormone therapy or placebo for at least one year. We included various oestrogen formulations, with or without progestogens. We focused on studies assessing hormone therapy's effects on long‐term clinical outcomes, including death, coronary events and cancer. Hormone therapy's efficacy in managing menopausal symptoms was beyond the scope of this review, and is assessed in other Cochrane reviews. Data collection and analysis Two review authors independently selected studies, assessed risk of bias and extracted data. We calculated risk ratios (RRs) for dichotomous data and mean differences (MDs) for continuous data, along with 95% confidence intervals (CIs). We assessed the certainty of the evidence using GRADE. Main results We included 24 studies – with two newly added in this update – involving 45,660 participants. We derived nearly 70% of the data from two well‐conducted studies: the Heart and Estrogen/progestin Replacement Study (HERS 1998) and the large, multi‐component Women's Health Initiative research programme, which included two hormone therapy arms (WHI 1998). Across all the studies, most participants were postmenopausal American women with one or more comorbidities. The mean participant age in most studies was over 60 years. Only one included study focused on perimenopausal women. We present full results for all included studies with available data in the main review. The results presented below are drawn from WHI 1998, in which the combined hormone therapy arm and the oestrogen‐only arm were run concurrently, with women assigned to the appropriate trial based on their uterus status. One study with 16,608 postmenopausal women with an intact uterus compared combined continuous hormone therapy (conjugated equine oestrogen and medroxyprogesterone acetate) to placebo, and measured outcomes at an average of 5.6 years of follow‐up. Based on this study, combined continuous hormone therapy probably makes little to no difference to the risk of a coronary event (RR 1.17, 95% CI 0.95 to 1.44; moderate‐certainty evidence). It may increase the risk of stroke (RR 1.39, 95% CI 1.09 to 2.09; low‐certainty evidence) and venous thromboembolism (RR 2.03, 95% CI 1.55 to 6.64; low‐certainty evidence). Compared to placebo, combined continuous hormone therapy probably increases the risk of breast cancer (RR 1.27, 95% CI 1.03 to 1.56; moderate‐certainty evidence) and probably makes little to no difference to the risk of lung cancer (RR 1.06, 95% CI 0.77 to 1.46; moderate‐certainty evidence). It may increase gallbladder disease requiring surgery (RR 1.64, 95% CI 1.30 to 2.06; 14,203 participants; low‐certainty evidence), and probably reduces the risk of all clinical fractures (RR 0.78, 95% CI 0.71 to 0.86; moderate‐certainty evidence). One study including 10,739 postmenopausal women who had undergone a hysterectomy compared oestrogen‐only (conjugated equine oestrogen) hormone therapy to placebo, and measured outcomes at an average of seven years' follow‐up. Based on this study, oestrogen‐only hormone therapy probably makes little to no difference to the risk of coronary events (RR 0.94, 95% CI 0.78 to 1.13), venous thromboembolism (RR 1.32, 95% CI 1.00 to 1.74) and breast cancer (RR 0.79, 95% CI 0.61 to 1.01), all with moderate‐certainty evidence. It may make little to no difference to the risk of lung cancer (RR 1.04, 95% CI 0.73 to 1.48; low‐certainty evidence). Oestrogen‐only hormone therapy probably increases the risk of stroke (RR 1.33, 95% CI 1.06 to 1.67) and gallbladder disease requiring surgery (RR 1.78, 95% CI 1.42 to 2.24), and probably reduces the risk of all clinical fractures (RR 0.73, 95% CI 0.65 to 0.80), all with moderate‐certainty evidence. We judged most included studies to have a low risk of bias for most domains. The overall certainty of evidence for the main comparisons was moderate. The main limitation was that only about 30% of women were 50 to 59 years old at baseline, the age group most likely to consider hormone therapy for vasomotor symptoms. Authors' conclusions Long‐term follow‐up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen‐only therapy. Oestrogen‐only hormone therapy probably makes little to no difference to coronary events, and probably increases the risk of stroke and gallbladder disease. It probably makes little to no difference in the risk of breast cancer, and probably reduces the risk of all fractures. Combined hormone therapy may increase the risk of thromboembolism and probably increases the risk of breast cancer. These results should be interpreted with caution as they are based on one study using oral hormone therapy, which may not represent the risks of the hormone therapy currently used in clinical practice.
- 27 November 2025
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2025 (11) , CD004143
Long-term hormone therapy for perimenopausal and postmenopausal women
Background Hormone therapy is widely provided to control menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. Objectives To assess the long‐term effects of prolonged use (at least one year) of hormone therapy on mortality, cardiovascular outcomes, cancer, gallbladder disease, fractures and cognition in perimenopausal and postmenopausal women. Search methods We used the Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL, MEDLINE, three other databases and two trial registers, together with reference checking, citation searching and contact with study authors to identify the studies included in the review. The latest search date was 26 September 2024. Selection criteria We included randomised, double‐blind trials in which peri‐ or postmenopausal women took hormone therapy or placebo for at least one year. We included various oestrogen formulations, with or without progestogens. We focused on studies assessing hormone therapy's effects on long‐term clinical outcomes, including death, coronary events and cancer. Hormone therapy's efficacy in managing menopausal symptoms was beyond the scope of this review, and is assessed in other Cochrane reviews. Data collection and analysis Two review authors independently selected studies, assessed risk of bias and extracted data. We calculated risk ratios (RRs) for dichotomous data and mean differences (MDs) for continuous data, along with 95% confidence intervals (CIs). We assessed the certainty of the evidence using GRADE. Main results We included 24 studies – with two newly added in this update – involving 45,660 participants. We derived nearly 70% of the data from two well‐conducted studies: the Heart and Estrogen/progestin Replacement Study (HERS 1998) and the large, multi‐component Women's Health Initiative research programme, which included two hormone therapy arms (WHI 1998). Across all the studies, most participants were postmenopausal American women with one or more comorbidities. The mean participant age in most studies was over 60 years. Only one included study focused on perimenopausal women. We present full results for all included studies with available data in the main review. The results presented below are drawn from WHI 1998, in which the combined hormone therapy arm and the oestrogen‐only arm were run concurrently, with women assigned to the appropriate trial based on their uterus status. One study with 16,608 postmenopausal women with an intact uterus compared combined continuous hormone therapy (conjugated equine oestrogen and medroxyprogesterone acetate) to placebo, and measured outcomes at an average of 5.6 years of follow‐up. Based on this study, combined continuous hormone therapy probably makes little to no difference to the risk of a coronary event (RR 1.17, 95% CI 0.95 to 1.44; moderate‐certainty evidence). It may increase the risk of stroke (RR 1.39, 95% CI 1.09 to 2.09; low‐certainty evidence) and venous thromboembolism (RR 2.03, 95% CI 1.55 to 6.64; low‐certainty evidence). Compared to placebo, combined continuous hormone therapy probably increases the risk of breast cancer (RR 1.27, 95% CI 1.03 to 1.56; moderate‐certainty evidence) and probably makes little to no difference to the risk of lung cancer (RR 1.06, 95% CI 0.77 to 1.46; moderate‐certainty evidence). It may increase gallbladder disease requiring surgery (RR 1.64, 95% CI 1.30 to 2.06; 14,203 participants; low‐certainty evidence), and probably reduces the risk of all clinical fractures (RR 0.78, 95% CI 0.71 to 0.86; moderate‐certainty evidence). One study including 10,739 postmenopausal women who had undergone a hysterectomy compared oestrogen‐only (conjugated equine oestrogen) hormone therapy to placebo, and measured outcomes at an average of seven years' follow‐up. Based on this study, oestrogen‐only hormone therapy probably makes little to no difference to the risk of coronary events (RR 0.94, 95% CI 0.78 to 1.13), venous thromboembolism (RR 1.32, 95% CI 1.00 to 1.74) and breast cancer (RR 0.79, 95% CI 0.61 to 1.01), all with moderate‐certainty evidence. It may make little to no difference to the risk of lung cancer (RR 1.04, 95% CI 0.73 to 1.48; low‐certainty evidence). Oestrogen‐only hormone therapy probably increases the risk of stroke (RR 1.33, 95% CI 1.06 to 1.67) and gallbladder disease requiring surgery (RR 1.78, 95% CI 1.42 to 2.24), and probably reduces the risk of all clinical fractures (RR 0.73, 95% CI 0.65 to 0.80), all with moderate‐certainty evidence. We judged most included studies to have a low risk of bias for most domains. The overall certainty of evidence for the main comparisons was moderate. The main limitation was that only about 30% of women were 50 to 59 years old at baseline, the age group most likely to consider hormone therapy for vasomotor symptoms. Authors' conclusions Long‐term follow‐up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen‐only therapy. Oestrogen‐only hormone therapy probably makes little to no difference to coronary events, and probably increases the risk of stroke and gallbladder disease. It probably makes little to no difference in the risk of breast cancer, and probably reduces the risk of all fractures. Combined hormone therapy may increase the risk of thromboembolism and probably increases the risk of breast cancer. These results should be interpreted with caution as they are based on one study using oral hormone therapy, which may not represent the risks of the hormone therapy currently used in clinical practice.
- 31 May 2022
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (2) , CD013180
Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis
Background Heavy menstrual bleeding (HMB) is excessive menstrual blood loss that interferes with women's quality of life, regardless of the absolute amount of bleeding. It is a very common condition in women of reproductive age, affecting 2 to 5 of every 10 women. Diverse treatments, either medical (hormonal or non‐hormonal) or surgical, are currently available for HMB, with different effectiveness, acceptability, costs and side effects. The best treatment will depend on the woman's age, her intention to become pregnant, the presence of other symptoms, and her personal views and preferences. Objectives To identify, systematically assess and summarise all evidence from studies included in Cochrane Reviews on treatment for heavy menstrual bleeding (HMB), using reviews with comparable participants and outcomes; and to present a ranking of the first‐ and second‐line treatments for HMB. Methods We searched for published Cochrane Reviews of HMB interventions in the Cochrane Database of Systematic Reviews. The primary outcomes were menstrual bleeding and satisfaction. Secondary outcomes included quality of life, adverse events and the requirement of further treatment. Two review authors independently selected the systematic reviews, extracted data and assessed quality, resolving disagreements by discussion. We assessed review quality using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) 2 tool and evaluated the certainty of the evidence for each outcome using GRADE methods. We grouped the interventions into first‐ and second‐line treatments, considering participant characteristics (desire for future pregnancy, failure of previous treatment, candidacy for surgery). First‐line treatments included medical interventions, and second‐line treatments included both the levonorgestrel‐releasing intrauterine system (LNG‐IUS) and surgical treatments; thus the LNG‐IUS is included in both groups. We developed different networks for first‐ and second‐line treatments. We performed network meta‐analyses of all outcomes, except for quality of life, where we performed pairwise meta‐analyses. We reported the mean rank, the network estimates for mean difference (MD) or odds ratio (OR), with 95% confidence intervals (CIs), and the certainty of evidence (moderate, low or very low certainty). We also analysed different endometrial ablation and resection techniques separately from the main network: transcervical endometrial resection (TCRE) with or without rollerball, other resectoscopic endometrial ablation (REA), microwave non‐resectoscopic endometrial ablation (NREA), hydrothermal ablation NREA, bipolar NREA, balloon NREA and other NREA. Main results We included nine systematic reviews published in the Cochrane Library up to July 2021. We updated the reviews that were over two years old. In July 2020, we started the overview with no new reviews about the topic. The included medical interventions were: non‐steroidal anti‐inflammatory drugs (NSAIDs), antifibrinolytics (tranexamic acid), combined oral contraceptives (COC), combined vaginal ring (CVR), long‐cycle and luteal oral progestogens, LNG‐IUS, ethamsylate and danazol (included to provide indirect evidence), which were compared to placebo. Surgical interventions were: open (abdominal), minimally invasive (vaginal or laparoscopic) and unspecified (or surgeon's choice of route of) hysterectomy, REA, NREA, unspecified endometrial ablation (EA) and LNG‐IUS. We grouped the interventions as follows. First‐line treatments Evidence from 26 studies with 1770 participants suggests that LNG‐IUS results in a large reduction of menstrual blood loss (MBL; mean rank 2.4, MD −105.71 mL/cycle, 95% CI −201.10 to −10.33; low certainty evidence); antifibrinolytics probably reduce MBL (mean rank 3.7, MD −80.32 mL/cycle, 95% CI −127.67 to −32.98; moderate certainty evidence); long‐cycle progestogen reduces MBL (mean rank 4.1, MD −76.93 mL/cycle, 95% CI −153.82 to −0.05; low certainty evidence), and NSAIDs slightly reduce MBL (mean rank 6.4, MD −40.67 mL/cycle, −84.61 to 3.27; low certainty evidence; reference comparator mean rank 8.9). We are uncertain of the true effect of the remaining interventions and the sensitivity analysis for reduction of MBL, as the evidence was rated as very low certainty. We are uncertain of the true effect of any intervention (very low certainty evidence) on the perception of improvement and satisfaction. Second‐line treatments Bleeding reduction is related to the type of hysterectomy (total or supracervical/subtotal), not the route, so we combined all routes of hysterectomy for bleeding outcomes. We assessed the reduction of MBL without imputed data (11 trials, 1790 participants) and with imputed data (15 trials, 2241 participants). Evidence without imputed data suggests that hysterectomy (mean rank 1.2, OR 25.71, 95% CI 1.50 to 439.96; low certainty evidence) and REA (mean rank 2.8, OR 2.70, 95% CI 1.29 to 5.66; low certainty evidence) result in a large reduction of MBL, and NREA probably results in a large reduction of MBL (mean rank 2.0, OR 3.32, 95% CI 1.53 to 7.23; moderate certainty evidence). Evidence with imputed data suggests hysterectomy results in a large reduction of MBL (mean rank 1.0, OR 14.31, 95% CI 2.99 to 68.56; low certainty evidence), and NREA probably results in a large reduction of MBL (mean rank 2.2, OR 2.87, 95% CI 1.29 to 6.05; moderate certainty evidence). We are uncertain of the true effect for REA (very low certainty evidence). We are uncertain of the effect on amenorrhoea (very low certainty evidence). Evidence from 27 trials with 4284 participants suggests that minimally invasive hysterectomy results in a large increase in satisfaction (mean rank 1.3, OR 7.96, 95% CI 3.33 to 19.03; low certainty evidence), and NREA also increases satisfaction (mean rank 3.6, OR 1.59, 95% CI 1.09 to 2.33; low certainty evidence), but we are uncertain of the true effect of the remaining interventions (very low certainty evidence). Authors' conclusions Evidence suggests LNG‐IUS is the best first‐line treatment for reducing menstrual blood loss (MBL); antifibrinolytics are probably the second best, and long‐cycle progestogens are likely the third best. We cannot make conclusions about the effect of first‐line treatments on perception of improvement and satisfaction, as evidence was rated as very low certainty. For second‐line treatments, evidence suggests hysterectomy is the best treatment for reducing bleeding, followed by REA and NREA. We are uncertain of the effect on amenorrhoea, as evidence was rated as very low certainty. Minimally invasive hysterectomy may result in a large increase in satisfaction, and NREA also increases satisfaction, but we are uncertain of the true effect of the remaining second‐line interventions, as evidence was rated as very low certainty.
- 31 May 2022
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2023 (2) , CD013180
Interventions for heavy menstrual bleeding; overview of Cochrane reviews and network meta-analysis
Background Heavy menstrual bleeding (HMB) is excessive menstrual blood loss that interferes with women's quality of life, regardless of the absolute amount of bleeding. It is a very common condition in women of reproductive age, affecting 2 to 5 of every 10 women. Diverse treatments, either medical (hormonal or non‐hormonal) or surgical, are currently available for HMB, with different effectiveness, acceptability, costs and side effects. The best treatment will depend on the woman's age, her intention to become pregnant, the presence of other symptoms, and her personal views and preferences. Objectives To identify, systematically assess and summarise all evidence from studies included in Cochrane Reviews on treatment for heavy menstrual bleeding (HMB), using reviews with comparable participants and outcomes; and to present a ranking of the first‐ and second‐line treatments for HMB. Methods We searched for published Cochrane Reviews of HMB interventions in the Cochrane Database of Systematic Reviews. The primary outcomes were menstrual bleeding and satisfaction. Secondary outcomes included quality of life, adverse events and the requirement of further treatment. Two review authors independently selected the systematic reviews, extracted data and assessed quality, resolving disagreements by discussion. We assessed review quality using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) 2 tool and evaluated the certainty of the evidence for each outcome using GRADE methods. We grouped the interventions into first‐ and second‐line treatments, considering participant characteristics (desire for future pregnancy, failure of previous treatment, candidacy for surgery). First‐line treatments included medical interventions, and second‐line treatments included both the levonorgestrel‐releasing intrauterine system (LNG‐IUS) and surgical treatments; thus the LNG‐IUS is included in both groups. We developed different networks for first‐ and second‐line treatments. We performed network meta‐analyses of all outcomes, except for quality of life, where we performed pairwise meta‐analyses. We reported the mean rank, the network estimates for mean difference (MD) or odds ratio (OR), with 95% confidence intervals (CIs), and the certainty of evidence (moderate, low or very low certainty). We also analysed different endometrial ablation and resection techniques separately from the main network: transcervical endometrial resection (TCRE) with or without rollerball, other resectoscopic endometrial ablation (REA), microwave non‐resectoscopic endometrial ablation (NREA), hydrothermal ablation NREA, bipolar NREA, balloon NREA and other NREA. Main results We included nine systematic reviews published in the Cochrane Library up to July 2021. We updated the reviews that were over two years old. In July 2020, we started the overview with no new reviews about the topic. The included medical interventions were: non‐steroidal anti‐inflammatory drugs (NSAIDs), antifibrinolytics (tranexamic acid), combined oral contraceptives (COC), combined vaginal ring (CVR), long‐cycle and luteal oral progestogens, LNG‐IUS, ethamsylate and danazol (included to provide indirect evidence), which were compared to placebo. Surgical interventions were: open (abdominal), minimally invasive (vaginal or laparoscopic) and unspecified (or surgeon's choice of route of) hysterectomy, REA, NREA, unspecified endometrial ablation (EA) and LNG‐IUS. We grouped the interventions as follows. First‐line treatments Evidence from 26 studies with 1770 participants suggests that LNG‐IUS results in a large reduction of menstrual blood loss (MBL; mean rank 2.4, MD −105.71 mL/cycle, 95% CI −201.10 to −10.33; low certainty evidence); antifibrinolytics probably reduce MBL (mean rank 3.7, MD −80.32 mL/cycle, 95% CI −127.67 to −32.98; moderate certainty evidence); long‐cycle progestogen reduces MBL (mean rank 4.1, MD −76.93 mL/cycle, 95% CI −153.82 to −0.05; low certainty evidence), and NSAIDs slightly reduce MBL (mean rank 6.4, MD −40.67 mL/cycle, −84.61 to 3.27; low certainty evidence; reference comparator mean rank 8.9). We are uncertain of the true effect of the remaining interventions and the sensitivity analysis for reduction of MBL, as the evidence was rated as very low certainty. We are uncertain of the true effect of any intervention (very low certainty evidence) on the perception of improvement and satisfaction. Second‐line treatments Bleeding reduction is related to the type of hysterectomy (total or supracervical/subtotal), not the route, so we combined all routes of hysterectomy for bleeding outcomes. We assessed the reduction of MBL without imputed data (11 trials, 1790 participants) and with imputed data (15 trials, 2241 participants). Evidence without imputed data suggests that hysterectomy (mean rank 1.2, OR 25.71, 95% CI 1.50 to 439.96; low certainty evidence) and REA (mean rank 2.8, OR 2.70, 95% CI 1.29 to 5.66; low certainty evidence) result in a large reduction of MBL, and NREA probably results in a large reduction of MBL (mean rank 2.0, OR 3.32, 95% CI 1.53 to 7.23; moderate certainty evidence). Evidence with imputed data suggests hysterectomy results in a large reduction of MBL (mean rank 1.0, OR 14.31, 95% CI 2.99 to 68.56; low certainty evidence), and NREA probably results in a large reduction of MBL (mean rank 2.2, OR 2.87, 95% CI 1.29 to 6.05; moderate certainty evidence). We are uncertain of the true effect for REA (very low certainty evidence). We are uncertain of the effect on amenorrhoea (very low certainty evidence). Evidence from 27 trials with 4284 participants suggests that minimally invasive hysterectomy results in a large increase in satisfaction (mean rank 1.3, OR 7.96, 95% CI 3.33 to 19.03; low certainty evidence), and NREA also increases satisfaction (mean rank 3.6, OR 1.59, 95% CI 1.09 to 2.33; low certainty evidence), but we are uncertain of the true effect of the remaining interventions (very low certainty evidence). Authors' conclusions Evidence suggests LNG‐IUS is the best first‐line treatment for reducing menstrual blood loss (MBL); antifibrinolytics are probably the second best, and long‐cycle progestogens are likely the third best. We cannot make conclusions about the effect of first‐line treatments on perception of improvement and satisfaction, as evidence was rated as very low certainty. For second‐line treatments, evidence suggests hysterectomy is the best treatment for reducing bleeding, followed by REA and NREA. We are uncertain of the effect on amenorrhoea, as evidence was rated as very low certainty. Minimally invasive hysterectomy may result in a large increase in satisfaction, and NREA also increases satisfaction, but we are uncertain of the true effect of the remaining second‐line interventions, as evidence was rated as very low certainty.
- 23 July 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (7)
Interventions commonly available during pandemics for heavy menstrual bleeding: an overview of Cochrane Reviews
Background Within the context of heavy menstrual bleeding, pandemics impact upon women's assessment and treatment by healthcare providers. Objectives To summarise the evidence from Cochrane Reviews evaluating interventions for heavy menstrual bleeding that are commonly available during pandemics. Methods We sought published Cochrane Reviews, evaluating interventions that can continue during pandemics for women with heavy menstrual bleeding with no known underlying cause. We identified Cochrane Reviews by searching the Cochrane Database of Systematic Reviews in June 2020. The primary outcome was menstrual bleeding. Secondary outcomes included quality of life, patient satisfaction, side effects, and serious adverse events. We undertook the selection of systematic reviews, data extraction, and quality assessment in duplicate. We resolved any disagreements by discussion. We assessed review quality using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) 2 tool, and the certainty of the evidence for each outcome using GRADE methods. Main results We included four Cochrane Reviews, with 11 comparisons, data from 44 randomised controlled trials (RCTs), and 3196 women. We assessed all the reviews to be high quality. Non‐steroidal anti‐inflammatory drugs (NSAIDs) NSAIDs may be more effective in reducing heavy menstrual bleeding than placebo (mean difference (MD) ‐124 mL per cycle, 95% confidence interval (CI) ‐186 to ‐62 mL per cycle; 1 RCT, 11 women; low‐certainty evidence). Mefenamic acid may be similar to naproxen (MD 21 mL per cycle, 95% CI ‐6 to 48 mL per cycle; 2 RCTs, 61 women; low‐certainty evidence), and NSAIDs may be similar to combined hormonal contraceptives for heavy menstrual bleeding (MD 25 mL per cycle, 95% CI ‐22 to 73 mL per cycle; 1 RCT, 26 women; low‐certainty evidence). NSAIDs may be be less effective in reducing menstrual bleeding than antifibrinolytics (relative risk (RR) 0.70, 95% CI 0.58 to 0.85; 2 RCTs, 161 women; low‐certainty evidence). We are uncertain whether NSAIDs reduce menstrual blood loss more than short‐cycle progestogens (RR 0.80, 95% CI 0.49 to 1.32; 1 RCT 32 women; very low‐certainty evidence). Antifibrinolytics Antifibrinolytics appear to be more effective in reducing heavy menstrual bleeding than placebo (MD ‐53 mL per cycle, 95% CI ‐63 to ‐44 mL per cycle; 4 RCTs, 565 women; moderate‐certainty evidence). Antifibrinolytics may be similar to placebo on the incidence of side effects (RR 1.05, 95% CI 0.93 to 1.18; 1 RCT, 297 women; low‐certainty evidence), and they are probably similar on the incidence of serious adverse events (thrombotic events; RR 0.10, 95% CI 0.00 to 2.46; 2 RCT, 468 women; moderate‐certainty evidence). Antifibrinolytics may be more effective in reducing heavy menstrual bleeding than short‐cycle progestogen (MD ‐111 mL per cycle, 95% CI ‐178 mL to ‐44 mL per cycle; 1 RCT, 46 women; low‐certainty evidence). We are uncertain whether antifibrinolytics are similar to short‐cycle progestogens on quality of life (RR 1.67, 95% CI 0.76 to 3.64; 1 RCT, 44 women; very low‐certainty evidence), patient satisfaction (RR 0.91, 95% CI 0.59 to 1.39; 1 RCT, 42 women; very low‐certainty evidence), or side effects (RR 0.85, 95% CI 0.65 to 1.12; 3 RCTs, 211 women; very low‐certainty evidence). We are uncertain whether antifibrinolytics are more effective in reducing heavy menstrual bleeding when compared with long‐cycle progestogen (MD ‐9 points per cycle, 95% CI ‐30 to 12 points per cycle; 2 RCTs, 184 women; low‐certainty evidence). Antifibrinolytics may increase self‐reported improvement in menstrual bleeding when compared with long‐cycle medroxyprogesterone acetate (RR 1.32, 95% CI 1.08 to 1.61; 1 RCT, 94 women; low‐certainty evidence). Antifibrinolytics may be similar to long‐cycle progestogens on quality of life (MD 5, 95% CI ‐2.49 to 12.49; 1 RCT, 90 women; low‐certainty evidence). We are uncertain whether antifibrinolytics are similar to long‐cycle progestogens on side effects (RR 0.58, 95% CI 0.33 to 1.00; 2 RCTs, 184 women; very low‐certainty evidence). There were no trials comparing antifibrinolytics to combined hormonal contraceptives. Combined hormonal contraceptives Combined hormonal contraceptives appear to be more effective for heavy menstrual bleeding than placebo or no treatment (RR 13.25, 95% CI 2.94 to 59.64; 2 RCTs, 363 women; moderate‐certainty evidence). Combined hormonal contraceptives are probably similar to placebo on the incidence of side effects (RR 1.53, 95% CI 0.90 to 2.60; 2 RCTs, 411 women; moderate‐certainty evidence). Progestogens There were no trials comparing progestogens to placebo. Limitations in the evidence included risk of bias in the primary RCTs, inconsistency between the primary RCTs, and imprecision in effect estimates. Authors' conclusions There is moderate‐certainty evidence that antifibrinolytics and combined hormonal contraceptives reduce heavy menstrual bleeding compared with placebo. There is low‐certainty evidence that NSAIDs reduce heavy menstrual bleeding compared with placebo. There is low‐certainty evidence that antifibrinolytics are more effective in reducing heavy menstrual bleeding when compared with NSAIDs and short‐cycle progestogens, but we are unable to draw conclusions about the effects of antifibrinolytics compared to long‐cycle progestogens, on low‐certainty evidence.
- 23 July 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (7)
Interventions commonly available during pandemics for heavy menstrual bleeding: an overview of Cochrane Reviews
Background Within the context of heavy menstrual bleeding, pandemics impact upon women's assessment and treatment by healthcare providers. Objectives To summarise the evidence from Cochrane Reviews evaluating interventions for heavy menstrual bleeding that are commonly available during pandemics. Methods We sought published Cochrane Reviews, evaluating interventions that can continue during pandemics for women with heavy menstrual bleeding with no known underlying cause. We identified Cochrane Reviews by searching the Cochrane Database of Systematic Reviews in June 2020. The primary outcome was menstrual bleeding. Secondary outcomes included quality of life, patient satisfaction, side effects, and serious adverse events. We undertook the selection of systematic reviews, data extraction, and quality assessment in duplicate. We resolved any disagreements by discussion. We assessed review quality using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) 2 tool, and the certainty of the evidence for each outcome using GRADE methods. Main results We included four Cochrane Reviews, with 11 comparisons, data from 44 randomised controlled trials (RCTs), and 3196 women. We assessed all the reviews to be high quality. Non‐steroidal anti‐inflammatory drugs (NSAIDs) NSAIDs may be more effective in reducing heavy menstrual bleeding than placebo (mean difference (MD) ‐124 mL per cycle, 95% confidence interval (CI) ‐186 to ‐62 mL per cycle; 1 RCT, 11 women; low‐certainty evidence). Mefenamic acid may be similar to naproxen (MD 21 mL per cycle, 95% CI ‐6 to 48 mL per cycle; 2 RCTs, 61 women; low‐certainty evidence), and NSAIDs may be similar to combined hormonal contraceptives for heavy menstrual bleeding (MD 25 mL per cycle, 95% CI ‐22 to 73 mL per cycle; 1 RCT, 26 women; low‐certainty evidence). NSAIDs may be be less effective in reducing menstrual bleeding than antifibrinolytics (relative risk (RR) 0.70, 95% CI 0.58 to 0.85; 2 RCTs, 161 women; low‐certainty evidence). We are uncertain whether NSAIDs reduce menstrual blood loss more than short‐cycle progestogens (RR 0.80, 95% CI 0.49 to 1.32; 1 RCT 32 women; very low‐certainty evidence). Antifibrinolytics Antifibrinolytics appear to be more effective in reducing heavy menstrual bleeding than placebo (MD ‐53 mL per cycle, 95% CI ‐63 to ‐44 mL per cycle; 4 RCTs, 565 women; moderate‐certainty evidence). Antifibrinolytics may be similar to placebo on the incidence of side effects (RR 1.05, 95% CI 0.93 to 1.18; 1 RCT, 297 women; low‐certainty evidence), and they are probably similar on the incidence of serious adverse events (thrombotic events; RR 0.10, 95% CI 0.00 to 2.46; 2 RCT, 468 women; moderate‐certainty evidence). Antifibrinolytics may be more effective in reducing heavy menstrual bleeding than short‐cycle progestogen (MD ‐111 mL per cycle, 95% CI ‐178 mL to ‐44 mL per cycle; 1 RCT, 46 women; low‐certainty evidence). We are uncertain whether antifibrinolytics are similar to short‐cycle progestogens on quality of life (RR 1.67, 95% CI 0.76 to 3.64; 1 RCT, 44 women; very low‐certainty evidence), patient satisfaction (RR 0.91, 95% CI 0.59 to 1.39; 1 RCT, 42 women; very low‐certainty evidence), or side effects (RR 0.85, 95% CI 0.65 to 1.12; 3 RCTs, 211 women; very low‐certainty evidence). We are uncertain whether antifibrinolytics are more effective in reducing heavy menstrual bleeding when compared with long‐cycle progestogen (MD ‐9 points per cycle, 95% CI ‐30 to 12 points per cycle; 2 RCTs, 184 women; low‐certainty evidence). Antifibrinolytics may increase self‐reported improvement in menstrual bleeding when compared with long‐cycle medroxyprogesterone acetate (RR 1.32, 95% CI 1.08 to 1.61; 1 RCT, 94 women; low‐certainty evidence). Antifibrinolytics may be similar to long‐cycle progestogens on quality of life (MD 5, 95% CI ‐2.49 to 12.49; 1 RCT, 90 women; low‐certainty evidence). We are uncertain whether antifibrinolytics are similar to long‐cycle progestogens on side effects (RR 0.58, 95% CI 0.33 to 1.00; 2 RCTs, 184 women; very low‐certainty evidence). There were no trials comparing antifibrinolytics to combined hormonal contraceptives. Combined hormonal contraceptives Combined hormonal contraceptives appear to be more effective for heavy menstrual bleeding than placebo or no treatment (RR 13.25, 95% CI 2.94 to 59.64; 2 RCTs, 363 women; moderate‐certainty evidence). Combined hormonal contraceptives are probably similar to placebo on the incidence of side effects (RR 1.53, 95% CI 0.90 to 2.60; 2 RCTs, 411 women; moderate‐certainty evidence). Progestogens There were no trials comparing progestogens to placebo. Limitations in the evidence included risk of bias in the primary RCTs, inconsistency between the primary RCTs, and imprecision in effect estimates. Authors' conclusions There is moderate‐certainty evidence that antifibrinolytics and combined hormonal contraceptives reduce heavy menstrual bleeding compared with placebo. There is low‐certainty evidence that NSAIDs reduce heavy menstrual bleeding compared with placebo. There is low‐certainty evidence that antifibrinolytics are more effective in reducing heavy menstrual bleeding when compared with NSAIDs and short‐cycle progestogens, but we are unable to draw conclusions about the effects of antifibrinolytics compared to long‐cycle progestogens, on low‐certainty evidence.
- 18 June 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (6)
Interventions commonly available during pandemics for heavy menstrual bleeding: an overview of Cochrane Reviews
This is a protocol for a Cochrane Review (overview). The objectives are as follows:
- 18 June 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (6)
Interventions commonly available during pandemics for heavy menstrual bleeding: an overview of Cochrane Reviews
This is a protocol for a Cochrane Review (overview). The objectives are as follows:
- 12 June 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (6) , CD002126
Progestogen-releasing intrauterine systems for heavy menstrual bleeding
Background Heavy menstrual bleeding (HMB) impacts the quality of life of otherwise healthy women. The perception of HMB is subjective and management depends upon, among other factors, the severity of the symptoms, a woman's age, her wish to get pregnant, and the presence of other pathologies. Heavy menstrual bleeding was classically defined as greater than or equal to 80 mL of blood loss per menstrual cycle. Currently the definition is based on the woman's perception of excessive bleeding which is affecting her quality of life. The intrauterine device was originally developed as a contraceptive but the addition of progestogens to these devices resulted in a large reduction in menstrual blood loss: users of the levonorgestrel‐releasing intrauterine system (LNG‐IUS) reported reductions of up to 90%. Insertion may, however, be regarded as invasive by some women, which affects its acceptability. Objectives To determine the effectiveness, acceptability and safety of progestogen‐releasing intrauterine devices in reducing heavy menstrual bleeding. Search methods We searched the Cochrane Gynaecology and Fertility Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO and CINAHL (from inception to June 2019); and we searched grey literature and for unpublished trials in trial registers. Selection criteria We included randomised controlled trials (RCTs) in women of reproductive age treated with LNG‐IUS devices versus no treatment, placebo, or other medical or surgical therapy for heavy menstrual bleeding. Data collection and analysis Two authors independently extracted data, assessed risk of bias and conducted GRADE assessments of the certainty of evidence. Main results We included 25 RCTs (2511 women). Limitations in the evidence included risk of attrition bias and low numbers of participants. The studies compared the following interventions. LNG‐IUS versus other medical therapy The other medical therapies were norethisterone acetate, medroxyprogesterone acetate, oral contraceptive pill, mefenamic acid, tranexamic acid or usual medical treatment (where participants could choose the oral treatment that was most suitable). The LNG‐IUS may improve HMB, lowering menstrual blood loss according to the alkaline haematin method (mean difference (MD) 66.91 mL, 95% confidence interval (CI) 42.61 to 91.20; 2 studies, 170 women; low‐certainty evidence); and the Pictorial Bleeding Assessment Chart (MD 55.05, 95% CI 27.83 to 82.28; 3 studies, 335 women; low‐certainty evidence). We are uncertain whether the LNG‐IUS may have any effect on women's satisfaction up to one year (RR 1.28, 95% CI 1.01 to 1.63; 3 studies, 141 women; I² = 0%, very low‐certainty evidence). The LNG‐IUS probably leads to slightly higher quality of life measured with the SF‐36 compared with other medical therapy (MD 2.90, 95% CI 0.06 to 5.74; 1 study: 571 women; moderate‐certainty evidence) or with the Menorrhagia Multi‐Attribute Scale (MD 13.40, 95% CI 9.89 to 16.91; 1 trial, 571 women; moderate‐certainty evidence). The LNG‐IUS and other medical therapies probably give rise to similar numbers of women with serious adverse events (RR 0.91, 95% CI 0.63 to 1.30; 1 study, 571 women; moderate‐certainty evidence). Women using other medical therapy are probably more likely to withdraw from treatment for any reason (RR 0.49, 95% CI 0.39 to 0.60; 1 study, 571 women, moderate‐certainty evidence) and to experience treatment failure than women with LNG‐IUS (RR 0.34, 95% CI 0.26 to 0.44; 6 studies, 535 women; moderate‐certainty evidence). LNG‐IUS versus endometrial resection or ablation (EA) Bleeding outcome results are inconsistent. We are uncertain of the effect of the LNG‐IUS compared to EA on rates of amenorrhoea (RR 1.21, 95% CI 0.85 to 1.72; 8 studies, 431 women; I² = 21%; low‐certainty evidence) and hypomenorrhoea (RR 0.98, 95% CI 0.73 to 1.33; 4 studies, 200 women; low‐certainty evidence) and eumenorrhoea (RR 0.55, 95% CI 0.30 to 1.00; 3 studies, 160 women; very low‐certainty evidence). We are uncertain whether both treatments may have similar rates of satisfaction with treatment at 12 months (RR 0.95, 95% CI 0.85 to 1.07; 5 studies, 317 women; low‐certainty evidence). We are uncertain if the LNG‐IUS compared to EA has any effect on quality of life, measured with SF‐36 (MD −14.40, 95% CI −22.63 to ‐6.17; 1 study, 33 women; very low‐certainty evidence). Women with the LNG‐IUS compared with EA are probably more likely to have any adverse event (RR 2.06, 95% CI 1.44 to 2.94; 3 studies, 201 women; moderate‐certainty evidence). Women with the LNG‐IUS may experience more treatment failure compared to EA at one year follow up (persistent HMB or requirement of additional treatment) (RR 1.78, 95% CI 1.09 to 2.90; 5 studies, 320 women; low‐certainty evidence); or requirement of hysterectomy may be higher at one year follow up (RR 2.56, 95% CI 1.48 to 4.42; 3 studies, 400 women; low‐certainty evidence). LNG‐IUS versus hysterectomy We are uncertain whether the LNG‐IUS has any effect on HMB compared with hysterectomy (RR for amenorrhoea 0.52, 95% CI 0.39 to 0.70; 1 study, 75 women; very low‐certainty evidence). We are uncertain whether there is difference between LNG‐IUS and hysterectomy in satisfaction at five years (RR 1.01, 95% CI 0.94 to 1.08; 1 study, 232 women; low‐certainty evidence) and quality of life (SF‐36 MD 2.20, 95% CI −2.93 to 7.33; 1 study, 221 women; low‐certainty evidence). Women in the LNG‐IUS group may be more likely to have treatment failure requiring hysterectomy for HMB at 1‐year follow‐up compared to the hysterectomy group (RR 48.18, 95% CI 2.96 to 783.22; 1 study, 236 women; low‐certainty evidence). None of the studies reported...
- 12 June 2020
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (6) , CD002126
Progestogen-releasing intrauterine systems for heavy menstrual bleeding
Background Heavy menstrual bleeding (HMB) impacts the quality of life of otherwise healthy women. The perception of HMB is subjective and management depends upon, among other factors, the severity of the symptoms, a woman's age, her wish to get pregnant, and the presence of other pathologies. Heavy menstrual bleeding was classically defined as greater than or equal to 80 mL of blood loss per menstrual cycle. Currently the definition is based on the woman's perception of excessive bleeding which is affecting her quality of life. The intrauterine device was originally developed as a contraceptive but the addition of progestogens to these devices resulted in a large reduction in menstrual blood loss: users of the levonorgestrel‐releasing intrauterine system (LNG‐IUS) reported reductions of up to 90%. Insertion may, however, be regarded as invasive by some women, which affects its acceptability. Objectives To determine the effectiveness, acceptability and safety of progestogen‐releasing intrauterine devices in reducing heavy menstrual bleeding. Search methods We searched the Cochrane Gynaecology and Fertility Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO and CINAHL (from inception to June 2019); and we searched grey literature and for unpublished trials in trial registers. Selection criteria We included randomised controlled trials (RCTs) in women of reproductive age treated with LNG‐IUS devices versus no treatment, placebo, or other medical or surgical therapy for heavy menstrual bleeding. Data collection and analysis Two authors independently extracted data, assessed risk of bias and conducted GRADE assessments of the certainty of evidence. Main results We included 25 RCTs (2511 women). Limitations in the evidence included risk of attrition bias and low numbers of participants. The studies compared the following interventions. LNG‐IUS versus other medical therapy The other medical therapies were norethisterone acetate, medroxyprogesterone acetate, oral contraceptive pill, mefenamic acid, tranexamic acid or usual medical treatment (where participants could choose the oral treatment that was most suitable). The LNG‐IUS may improve HMB, lowering menstrual blood loss according to the alkaline haematin method (mean difference (MD) 66.91 mL, 95% confidence interval (CI) 42.61 to 91.20; 2 studies, 170 women; low‐certainty evidence); and the Pictorial Bleeding Assessment Chart (MD 55.05, 95% CI 27.83 to 82.28; 3 studies, 335 women; low‐certainty evidence). We are uncertain whether the LNG‐IUS may have any effect on women's satisfaction up to one year (RR 1.28, 95% CI 1.01 to 1.63; 3 studies, 141 women; I² = 0%, very low‐certainty evidence). The LNG‐IUS probably leads to slightly higher quality of life measured with the SF‐36 compared with other medical therapy (MD 2.90, 95% CI 0.06 to 5.74; 1 study: 571 women; moderate‐certainty evidence) or with the Menorrhagia Multi‐Attribute Scale (MD 13.40, 95% CI 9.89 to 16.91; 1 trial, 571 women; moderate‐certainty evidence). The LNG‐IUS and other medical therapies probably give rise to similar numbers of women with serious adverse events (RR 0.91, 95% CI 0.63 to 1.30; 1 study, 571 women; moderate‐certainty evidence). Women using other medical therapy are probably more likely to withdraw from treatment for any reason (RR 0.49, 95% CI 0.39 to 0.60; 1 study, 571 women, moderate‐certainty evidence) and to experience treatment failure than women with LNG‐IUS (RR 0.34, 95% CI 0.26 to 0.44; 6 studies, 535 women; moderate‐certainty evidence). LNG‐IUS versus endometrial resection or ablation (EA) Bleeding outcome results are inconsistent. We are uncertain of the effect of the LNG‐IUS compared to EA on rates of amenorrhoea (RR 1.21, 95% CI 0.85 to 1.72; 8 studies, 431 women; I² = 21%; low‐certainty evidence) and hypomenorrhoea (RR 0.98, 95% CI 0.73 to 1.33; 4 studies, 200 women; low‐certainty evidence) and eumenorrhoea (RR 0.55, 95% CI 0.30 to 1.00; 3 studies, 160 women; very low‐certainty evidence). We are uncertain whether both treatments may have similar rates of satisfaction with treatment at 12 months (RR 0.95, 95% CI 0.85 to 1.07; 5 studies, 317 women; low‐certainty evidence). We are uncertain if the LNG‐IUS compared to EA has any effect on quality of life, measured with SF‐36 (MD −14.40, 95% CI −22.63 to ‐6.17; 1 study, 33 women; very low‐certainty evidence). Women with the LNG‐IUS compared with EA are probably more likely to have any adverse event (RR 2.06, 95% CI 1.44 to 2.94; 3 studies, 201 women; moderate‐certainty evidence). Women with the LNG‐IUS may experience more treatment failure compared to EA at one year follow up (persistent HMB or requirement of additional treatment) (RR 1.78, 95% CI 1.09 to 2.90; 5 studies, 320 women; low‐certainty evidence); or requirement of hysterectomy may be higher at one year follow up (RR 2.56, 95% CI 1.48 to 4.42; 3 studies, 400 women; low‐certainty evidence). LNG‐IUS versus hysterectomy We are uncertain whether the LNG‐IUS has any effect on HMB compared with hysterectomy (RR for amenorrhoea 0.52, 95% CI 0.39 to 0.70; 1 study, 75 women; very low‐certainty evidence). We are uncertain whether there is difference between LNG‐IUS and hysterectomy in satisfaction at five years (RR 1.01, 95% CI 0.94 to 1.08; 1 study, 232 women; low‐certainty evidence) and quality of life (SF‐36 MD 2.20, 95% CI −2.93 to 7.33; 1 study, 221 women; low‐certainty evidence). Women in the LNG‐IUS group may be more likely to have treatment failure requiring hysterectomy for HMB at 1‐year follow‐up compared to the hysterectomy group (RR 48.18, 95% CI 2.96 to 783.22; 1 study, 236 women; low‐certainty evidence). None of the studies reported...
- 14 August 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 8 (8) , CD001016
Cyclical progestogens for heavy menstrual bleeding
Background Heavy menstrual bleeding (HMB) is a menstrual blood loss perceived by women as excessive that affects the health of women of reproductive age, interfering with their physical, emotional, social and material quality of life. Whilst abnormal menstrual bleeding may be associated with underlying pathology, in the present context, HMB is defined as excessive menstrual bleeding in the absence of other systemic or gynaecological disease. The first‐line therapy is usually medical, avoiding possibly unnecessary surgery. Of the wide variety of medications used to reduce HMB, oral progestogens were originally the most commonly prescribed agents. This review assesses the effectiveness of two different types and regimens of oral progestogens in reducing ovulatory HMB. This is the update of a Cochrane review last updated in 2007, and originally named "Effectiveness of cyclical progestagen therapy in reducing heavy menstrual bleeding" (1998). Objectives To determine the effectiveness, safety and tolerability of oral progestogen therapy taken either during the luteal phase (short cycle) or for a longer course of 21 days per cycle (long cycle), in achieving a reduction in menstrual blood loss in women of reproductive age with HMB. Search methods In January 2019 we searched Cochrane Gynaecology and Fertility's specialized register, CENTRAL, MEDLINE, Embase, CINAHL and PsycInfo. We also searched trials registers, other sources of unpublished or grey literature and reference lists of retrieved trials. We also checked citation lists of review articles to identify trials. Selection criteria Randomized controlled trials (RCTs) comparing different treatments for HMB that included cyclical oral progestogens were eligible. Data collection and analysis Two review authors independently selected trials for inclusion, assessed trials for risk of bias and extracted data. We contacted trial authors for clarification of methods or additional data when necessary. We only assessed adverse events if they were separately measured in the included trials. We compared cyclical oral progestogen in different regimens and placebo or other treatments. Our primary outcomes were menstrual blood loss and satisfaction with treatment; the secondary outcomes were number of days of bleeding, quality of life, compliance and acceptability of treatment, adverse events and costs. Main results This review identified 15 randomized controlled trials (RCTs) with 1071 women in total. Most of the women knew which treatment they were receiving, which may have influenced their judgements about menstrual blood loss and satisfaction. Other aspects of trial quality varied among trials. We did not identify any RCTs comparing progestogen treatment with placebo. We assessed comparisons between oral progestogens and other medical therapies separately according to different regimens. Short‐cycle progestogen therapy during the luteal phase (medroxyprogesterone acetate or norethisterone for 7 to 10 days, from day 15 to 19) was inferior to other medical therapy, including tranexamic acid, danazol and the progestogen‐releasing intrauterine system (Pg‐IUS (off the market since 2001)), releasing 60 mcg of progesterone daily, with respect to reduction of menstrual blood loss (mean difference (MD) 37.29, 95% confidence interval (CI) 17.67 to 56.91; I2 = 50%; 6 trials, 145 women, low‐quality evidence). The rate of satisfaction and the quality of life with treatment was similar in both groups. The number of bleeding days was greater on the short cycle progestogen group compared to other medical treatments. Adverse events (such as gastrointestinal symptoms and weight gain) were more likely with danazol when compared with progestogen treatment. We note that danazol is no longer in general use for treating HMB. Long‐cycle progestogen therapy (medroxyprogesterone acetate or norethisterone), from day 5 to day 26 of the menstrual cycle, is also inferior compared to the levonorgestrel‐releasing intrauterine system (LNG‐IUS), tranexamic acid and ormeloxifene, but may be similar to the combined vaginal ring with respect to reduction of menstrual blood loss (MD 16.88, 95% CI 10.93 to 22.84; I2 = 87%; 4 trials, 355 women, very low‐quality evidence). There was no clear evidence of a difference between progestogen therapy long cycle and other medical therapy in terms of headache (OR 1.45, 95% CI 0.40 to 5.31; I2 = 0%; 2 trials, 189 women; low‐quality evidence). Breakthrough bleeding or spotting was more likely in women with the LNG‐IUS (OR 0.18, 95% CI 0.06 to 0.55; I2 = 0%; 3 trials, 220 women; low‐quality evidence). No trials reported on days of bleeding or quality of life for this comparison. The evidence supporting these findings was limited by low or very low gradings of quality; thus, we are uncertain about the findings and there is a potential that they may change if we identify other trials. Authors' conclusions Low‐ or very low‐quality evidence suggests that short‐course progestogen was inferior to other medical therapy, including tranexamic acid, danazol and the Pg‐IUS with respect to reduction of menstrual blood loss. Long cycle progestogen therapy (medroxyprogesterone acetate or norethisterone) was also inferior to the LNG‐IUS, tranexamic acid and ormeloxifene, but may be similar to the combined vaginal ring with respect to reduction of menstrual blood loss.
- 14 August 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 8 (8) , CD001016
Cyclical progestogens for heavy menstrual bleeding
Background Heavy menstrual bleeding (HMB) is a menstrual blood loss perceived by women as excessive that affects the health of women of reproductive age, interfering with their physical, emotional, social and material quality of life. Whilst abnormal menstrual bleeding may be associated with underlying pathology, in the present context, HMB is defined as excessive menstrual bleeding in the absence of other systemic or gynaecological disease. The first‐line therapy is usually medical, avoiding possibly unnecessary surgery. Of the wide variety of medications used to reduce HMB, oral progestogens were originally the most commonly prescribed agents. This review assesses the effectiveness of two different types and regimens of oral progestogens in reducing ovulatory HMB. This is the update of a Cochrane review last updated in 2007, and originally named "Effectiveness of cyclical progestagen therapy in reducing heavy menstrual bleeding" (1998). Objectives To determine the effectiveness, safety and tolerability of oral progestogen therapy taken either during the luteal phase (short cycle) or for a longer course of 21 days per cycle (long cycle), in achieving a reduction in menstrual blood loss in women of reproductive age with HMB. Search methods In January 2019 we searched Cochrane Gynaecology and Fertility's specialized register, CENTRAL, MEDLINE, Embase, CINAHL and PsycInfo. We also searched trials registers, other sources of unpublished or grey literature and reference lists of retrieved trials. We also checked citation lists of review articles to identify trials. Selection criteria Randomized controlled trials (RCTs) comparing different treatments for HMB that included cyclical oral progestogens were eligible. Data collection and analysis Two review authors independently selected trials for inclusion, assessed trials for risk of bias and extracted data. We contacted trial authors for clarification of methods or additional data when necessary. We only assessed adverse events if they were separately measured in the included trials. We compared cyclical oral progestogen in different regimens and placebo or other treatments. Our primary outcomes were menstrual blood loss and satisfaction with treatment; the secondary outcomes were number of days of bleeding, quality of life, compliance and acceptability of treatment, adverse events and costs. Main results This review identified 15 randomized controlled trials (RCTs) with 1071 women in total. Most of the women knew which treatment they were receiving, which may have influenced their judgements about menstrual blood loss and satisfaction. Other aspects of trial quality varied among trials. We did not identify any RCTs comparing progestogen treatment with placebo. We assessed comparisons between oral progestogens and other medical therapies separately according to different regimens. Short‐cycle progestogen therapy during the luteal phase (medroxyprogesterone acetate or norethisterone for 7 to 10 days, from day 15 to 19) was inferior to other medical therapy, including tranexamic acid, danazol and the progestogen‐releasing intrauterine system (Pg‐IUS (off the market since 2001)), releasing 60 mcg of progesterone daily, with respect to reduction of menstrual blood loss (mean difference (MD) 37.29, 95% confidence interval (CI) 17.67 to 56.91; I2 = 50%; 6 trials, 145 women, low‐quality evidence). The rate of satisfaction and the quality of life with treatment was similar in both groups. The number of bleeding days was greater on the short cycle progestogen group compared to other medical treatments. Adverse events (such as gastrointestinal symptoms and weight gain) were more likely with danazol when compared with progestogen treatment. We note that danazol is no longer in general use for treating HMB. Long‐cycle progestogen therapy (medroxyprogesterone acetate or norethisterone), from day 5 to day 26 of the menstrual cycle, is also inferior compared to the levonorgestrel‐releasing intrauterine system (LNG‐IUS), tranexamic acid and ormeloxifene, but may be similar to the combined vaginal ring with respect to reduction of menstrual blood loss (MD 16.88, 95% CI 10.93 to 22.84; I2 = 87%; 4 trials, 355 women, very low‐quality evidence). There was no clear evidence of a difference between progestogen therapy long cycle and other medical therapy in terms of headache (OR 1.45, 95% CI 0.40 to 5.31; I2 = 0%; 2 trials, 189 women; low‐quality evidence). Breakthrough bleeding or spotting was more likely in women with the LNG‐IUS (OR 0.18, 95% CI 0.06 to 0.55; I2 = 0%; 3 trials, 220 women; low‐quality evidence). No trials reported on days of bleeding or quality of life for this comparison. The evidence supporting these findings was limited by low or very low gradings of quality; thus, we are uncertain about the findings and there is a potential that they may change if we identify other trials. Authors' conclusions Low‐ or very low‐quality evidence suggests that short‐course progestogen was inferior to other medical therapy, including tranexamic acid, danazol and the Pg‐IUS with respect to reduction of menstrual blood loss. Long cycle progestogen therapy (medroxyprogesterone acetate or norethisterone) was also inferior to the LNG‐IUS, tranexamic acid and ormeloxifene, but may be similar to the combined vaginal ring with respect to reduction of menstrual blood loss.
- 15 November 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (11)
Interventions for the treatment of heavy menstrual bleeding
This is a protocol for a Cochrane Review (Overview). The objectives are as follows: To identify, systematically assess and summarise all evidence from Cochrane Reviews on treatment for heavy menstrual bleeding (HMB), through a network meta‐analysis. To compare the efficacy, satisfaction and safety of different treatments available for HMB (that have been assessed in Cochrane Reviews), performing direct and indirect comparisons through a network meta‐analysis.
- 15 November 2018
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2018 (11)
Interventions for the treatment of heavy menstrual bleeding
This is a protocol for a Cochrane Review (Overview). The objectives are as follows: To identify, systematically assess and summarise all evidence from Cochrane Reviews on treatment for heavy menstrual bleeding (HMB), through a network meta‐analysis. To compare the efficacy, satisfaction and safety of different treatments available for HMB (that have been assessed in Cochrane Reviews), performing direct and indirect comparisons through a network meta‐analysis.